David Miyamoto, MD, PhD is an Assistant Professor of Radiation Oncology at Harvard Medical School, an attending radiation oncologist at the Massachusetts General Hospital (MGH) and a physician scientist in the MGH Center for Cancer Research. Dr. Miyamoto received his undergraduate degree in Chemistry from Harvard College, MD from Harvard Medical School, and PhD in Cell Biology from Harvard University. He completed an internship in Internal Medicine at the Brigham & Women's Hospital, and his residency in radiation oncology in the Harvard Radiation Oncology Program. Dr. Miyamoto is a board-certified radiation oncologist specializing in genitourinary malignancies who sees patients in the Bertucci Center for Genitourinary Cancers at the MGH Cancer Center and the MGH Department of Radiation Oncology. His research efforts focus on the development of novel biomarkers to guide prostate cancer and bladder cancer therapy, and the development of sensitive microfluidic platforms for the molecular analysis of circulating tumor cells (CTCs). He has authored and co-authored more than 35 publications in peer-reviewed scientific journals including Science, Cell, and Cancer Discovery. His research has been supported by the Prostate Cancer Foundation, Department of Defense, National Cancer Institute, and the Dana Farber/Harvard Cancer Center.